Zacks Investment Research cut shares of SLS International (AMEX:SLS) from a hold rating to a sell rating in a report released on Wednesday morning.
According to Zacks, “SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company’s product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present in an array of tumor types. SELLAS Life Sciences Group Inc., formerly known as Galena Biopharma Inc., is based in NEW YORK, United States. “
Other analysts also recently issued reports about the stock. Maxim Group set a $5.00 target price on shares of SLS International and gave the stock a buy rating in a research report on Thursday, December 6th. Oppenheimer set a $13.00 target price on shares of SLS International and gave the stock a buy rating in a research report on Thursday, November 15th. Finally, CIBC assumed coverage on shares of SLS International in a research report on Thursday, November 1st. They issued an outperform rating on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $5.81.
In other news, insider Angelos M. Stergiou sold 23,277 shares of the company’s stock in a transaction dated Monday, December 31st. The shares were sold at an average price of $1.25, for a total value of $29,096.25. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.76% of the stock is owned by corporate insiders.
About SLS International
SLS international is a language services company which offers translations globally. The Company offers a range of services, including multilingual translations into all Spanish variants, localization, adaptation and content editing. It uses the mother-tongue linguists in order to meet the demanding standards.
See Also: Should You Consider an Index Fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SLS International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SLS International and related companies with MarketBeat.com's FREE daily email newsletter.